Moneycontrol PRO
you are here: HomeNewsWorld

Mark Mobius says the bottom is here, shops for pharma and luxury stocks

The veteran investor has embarked on a buying spree and sees value in select pharma and luxury stocks that were roiled by the onset of the novel coronavirus.

March 31, 2020 / 04:02 PM IST

Emerging markets expert Mark Mobius has said he is buying into the selloff driven by the coronavirus, as the market may have already hit the bottom.

The veteran investor has embarked on a buying spree and sees value in select pharma and luxury stocks roiled by the onset of the coronavirus outbreak.

“Indices around the world have not been much different from what we’ve seen in history. If you look at bear markets since 1987, you find the average decline is about 50 percent, and the average length of time from the peak to the bottom is a little less than three years," Mobius said in an interview to Financial News.

“We may have already hit the bottom. The difference this time is the massive bailout programmes that are feeding money into the market. Whenever you see a massive flow of cash coming into the market, equities will adjust.” he added.

The founder of Mobius Capital Partners LLP is bolstering his personal portfolio with healthcare and pharmaceutical companies, as well as those focused on luxury brands such as LVMH.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

“All of these are down, but they are not going to stay down. I’m doing it gradually,” he said.

The coronavirus, which emerged in the Chinese city of Wuhan in late 2019, has now spread to 202 countries and territories, killing more than 38,000 people and leaving hundreds of thousands in quarantine.

The highly infectious virus is spreading rapidly in Europe and the United States, forcing shut down of offices, schools, cafes, cinema halls, malls, upending normal life.

India has also seen infections inch up. It has, so far, reported 32 deaths and 1,251 cases.

The pandemic has roiled equity markets across the globe. All major indices have tanked more than 20 percent from their January levels. Both the Nifty and the Sensex have fallen almost 30 percent from their all-time intraday highs touched on January 16, 2020.
Moneycontrol News
first published: Mar 31, 2020 04:02 pm
ISO 27001 - BSI Assurance Mark